# Safety and Efficacy of the Bispecific T-Cell Engager (BiTE) as Conditioning Regimen for ABO-incompatible Living Donor Kidney Transplantation

> **NCT07706205** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **West China Hospital** · enrollment: 20 (estimated)

## Conditions studied

- ABO Blood Type Incompatible Kidney Transplantation

## Interventions

- **DRUG:** Blinatumomab Treatment
- **DRUG:** Teclistamab treat

## Key facts

- **NCT ID:** NCT07706205
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07706205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07706205, "Safety and Efficacy of the Bispecific T-Cell Engager (BiTE) as Conditioning Regimen for ABO-incompatible Living Donor Kidney Transplantation". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07706205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*